ES2164447T3 - Procedimiento de inhibicion de resorcion del hueso. - Google Patents

Procedimiento de inhibicion de resorcion del hueso.

Info

Publication number
ES2164447T3
ES2164447T3 ES98935752T ES98935752T ES2164447T3 ES 2164447 T3 ES2164447 T3 ES 2164447T3 ES 98935752 T ES98935752 T ES 98935752T ES 98935752 T ES98935752 T ES 98935752T ES 2164447 T3 ES2164447 T3 ES 2164447T3
Authority
ES
Spain
Prior art keywords
resortion
bone
inhibition procedure
inhibition
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98935752T
Other languages
English (en)
Inventor
Anastasia G Daifotis
Arthur C Ii Santora
A John Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2164447(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2164447T3 publication Critical patent/ES2164447T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Pit Excavations, Shoring, Fill Or Stabilisation Of Slopes (AREA)
  • Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención se refiere a procedimientos de inhibición de resorción ósea en los mamíferos a la vez que se minimiza la aparición o el riesgo de efectos secundarios gastrointestinales. La invenciones refiere también a las composiciones farmacéuticas y los conjuntos que permiten la puesta en práctica de los procedimientos terapéuticos.
ES98935752T 1997-07-22 1998-07-17 Procedimiento de inhibicion de resorcion del hueso. Expired - Lifetime ES2164447T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Publications (1)

Publication Number Publication Date
ES2164447T3 true ES2164447T3 (es) 2002-02-16

Family

ID=27451690

Family Applications (3)

Application Number Title Priority Date Filing Date
ES98935752T Expired - Lifetime ES2164447T3 (es) 1997-07-22 1998-07-17 Procedimiento de inhibicion de resorcion del hueso.
ES01201913T Expired - Lifetime ES2269014T3 (es) 1997-07-22 1998-07-17 Procedimiento para inhibir la resorcion osea.
ES01201910T Pending ES2253136T1 (es) 1997-07-22 1998-07-17 Procedimiento para inhibir la resorcion osea.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES01201913T Expired - Lifetime ES2269014T3 (es) 1997-07-22 1998-07-17 Procedimiento para inhibir la resorcion osea.
ES01201910T Pending ES2253136T1 (es) 1997-07-22 1998-07-17 Procedimiento para inhibir la resorcion osea.

Country Status (31)

Country Link
EP (5) EP1175904B8 (es)
JP (2) JP3479780B2 (es)
KR (3) KR20030097611A (es)
CN (3) CN1602879A (es)
AT (2) ATE209037T1 (es)
AU (1) AU8493698A (es)
BG (1) BG66282B1 (es)
BR (1) BR9810779A (es)
CA (1) CA2294595C (es)
CY (2) CY1107535T1 (es)
DE (6) DE122006000009I1 (es)
DK (2) DK0998292T3 (es)
EA (1) EA004544B2 (es)
EE (1) EE05603B1 (es)
ES (3) ES2164447T3 (es)
HK (5) HK1024166A1 (es)
ID (1) ID24096A (es)
IL (1) IL133535A0 (es)
IS (3) IS5315A (es)
LU (2) LU91222I2 (es)
NL (2) NL300223I1 (es)
NO (1) NO20000323L (es)
NZ (1) NZ501807A (es)
PL (1) PL195272B1 (es)
PT (2) PT1175904E (es)
SG (2) SG139556A1 (es)
SI (1) SI0998292T1 (es)
SK (1) SK932000A3 (es)
TR (1) TR200000145T2 (es)
UY (1) UY25950A1 (es)
WO (1) WO1999004773A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6727233B1 (en) * 1998-12-25 2004-04-27 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions for treating osseous lesion in multiple myeloma
BR0010808A (pt) * 1999-05-21 2002-08-27 Novartis Ag Composições farmacêuticas e usos
DE60043648D1 (de) * 1999-07-19 2010-02-25 Toray Industries Medikamente zur behandlung von periodontalen erkrankungen
WO2001046040A1 (en) 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card
WO2001045636A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Pharmaceutical kit
BR0110316A (pt) * 2000-04-07 2005-01-18 Regents For The University Of Composições únicas de fosfolipìdios e bisfosfonatos zwitteriÈnicos e uso das composições como sistemas de distribuição de bisfosfatos com toxicidade gi reduzida
NZ523086A (en) 2000-06-20 2007-07-27 Novartis Ag Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
KR20120065435A (ko) * 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
SE0203065D0 (sv) * 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
JPWO2005072747A1 (ja) * 2004-02-02 2007-09-13 小野薬品工業株式会社 骨吸収抑制剤
AU2006290519B2 (en) * 2005-09-16 2012-10-18 Selamine Ltd Bisphosphonate formulation
BR112013010476B1 (pt) * 2010-12-06 2021-07-06 Effrx Pharmaceuticals Sa formulações efervescentes estáveis de bisfosfonato com características de solubilização rápida
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
DE59202126D1 (de) * 1991-07-01 1995-06-14 Gergely Gerhard Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung.
KR100274734B1 (ko) * 1991-11-22 2000-12-15 제이코버스 코넬리스 레이서 리제드로네이트 지연-방출성 조성물
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
JP4481368B2 (ja) * 1992-06-30 2010-06-16 味の素株式会社 骨粗鬆症の治療用のためのホスホネート類の用途
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
AU712710B2 (en) * 1996-05-17 1999-11-11 Merck Sharp & Dohme Corp. Effervescent bisphosphonate formulation

Also Published As

Publication number Publication date
EP0998292B1 (en) 2001-11-21
UY25950A1 (es) 2000-09-29
ID24096A (id) 2000-07-06
BG104093A (en) 2000-10-31
HK1042230A1 (zh) 2002-08-09
EP1175904B8 (en) 2007-05-09
ES2269014T3 (es) 2007-05-01
IS7230A (is) 2004-04-21
IS5315A (is) 1999-12-21
NL300292I1 (nl) 2007-11-01
DE69837450D1 (de) 2007-05-10
EA004544B2 (ru) 2006-12-29
PT998292E (pt) 2002-04-29
EP1151752A3 (en) 2002-12-18
EP1151752A2 (en) 2001-11-07
EA004544B1 (ru) 2004-06-24
EP1175904B1 (en) 2007-03-28
EP1132088A3 (en) 2002-04-24
PL195272B1 (pl) 2007-08-31
DK0998292T3 (da) 2002-05-13
AU8493698A (en) 1999-02-16
DK1175904T3 (da) 2007-05-07
ATE357921T1 (de) 2007-04-15
EP1175904A3 (en) 2002-12-18
HK1040494A1 (zh) 2002-06-14
ATE209037T1 (de) 2001-12-15
CN1299689C (zh) 2007-02-14
SI0998292T1 (en) 2002-04-30
BR9810779A (pt) 2000-07-25
KR100391732B1 (ko) 2003-07-16
HK1040495A1 (zh) 2002-06-14
DE69837450T2 (de) 2007-08-23
WO1999004773A2 (en) 1999-02-04
EA200000151A1 (ru) 2000-10-30
DE01201913T1 (de) 2007-02-08
WO1999004773A9 (en) 1999-10-28
DE69803291T2 (de) 2002-08-08
BG66282B1 (bg) 2013-01-31
ES2253136T1 (es) 2006-06-01
JP2002502433A (ja) 2002-01-22
CN1602879A (zh) 2005-04-06
EP1132088A2 (en) 2001-09-12
CA2294595A1 (en) 1999-02-04
EP1175903A2 (en) 2002-01-30
PT1175904E (pt) 2007-04-30
CN1166365C (zh) 2004-09-15
NL300223I1 (nl) 2006-04-03
CN1602880A (zh) 2005-04-06
IS7231A (is) 2004-04-21
DE122006000009I1 (de) 2006-06-14
CY2007022I2 (el) 2012-01-25
TR200000145T2 (tr) 2000-05-22
NO20000323L (no) 2000-03-20
ES2269014T1 (es) 2007-04-01
EE05603B1 (et) 2012-12-17
EE200000040A (et) 2000-10-16
EP1175904A2 (en) 2002-01-30
WO1999004773A3 (en) 1999-04-15
KR20010022110A (ko) 2001-03-15
DE69803291D1 (de) 2002-02-21
PL338635A1 (en) 2000-11-06
HK1042232A1 (zh) 2002-08-09
SG109478A1 (en) 2005-03-30
DE01201911T1 (de) 2007-10-18
JP3479780B2 (ja) 2003-12-15
LU91364I2 (fr) 2007-11-12
JP2005068010A (ja) 2005-03-17
NO20000323D0 (no) 2000-01-21
SG139556A1 (en) 2008-02-29
DE122007000063I1 (de) 2007-12-20
CY2007022I1 (el) 2012-01-25
NZ501807A (en) 2003-02-28
CN1265035A (zh) 2000-08-30
CA2294595C (en) 2001-08-21
KR20030097610A (ko) 2003-12-31
EP0998292A2 (en) 2000-05-10
CY1107535T1 (el) 2012-01-25
HK1024166A1 (en) 2000-10-05
SK932000A3 (en) 2000-09-12
IL133535A0 (en) 2001-04-30
LU91222I2 (fr) 2006-04-18
KR20030097611A (ko) 2003-12-31
EP1175903A3 (en) 2002-12-18

Similar Documents

Publication Publication Date Title
ES2164447T3 (es) Procedimiento de inhibicion de resorcion del hueso.
PT705100E (pt) Guanidinas substituidas terapeuticas
SE9901272D0 (sv) New improved formulation
CO5160265A1 (es) Esteres aminoacidos de ribavirina y composiciones farmaceuticas que los contienen .
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
DK1009399T3 (da) GABA-analoger til forebyggelse og behandling af gastrointestinal skade
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
FI941826A (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
BG104599A (en) Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
DK1914237T3 (da) Antivirale fosfonatesterforbindelser
BR0008059A (pt) Composições de valdecoxib
DK0758241T3 (da) Anvendelse af visse methanbisphosphonsyrederivater til at hindre løsning og vandring af proteser
ES2194107T3 (es) Formulaciones farmaceuticas y dieteticas para la profilaxis y tratamiento de trastornos gastrointestinales.
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
DK0951909T3 (da) Kombinationspræparat omfattende en L-carnitin eller en alkanoyl-L-carnitin, en glycosaminoglycan og/eller bestanddel deraf
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
NO964238D0 (no) Halofantrin-fri-base for behandling av malaria og blandinger
DK1073436T3 (da) Forbedret fremgangsmåde til udryddelse af helicobacter pylori
NO990450L (no) Behandling av sinnslidelser
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
HU0201738D0 (es)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 998292

Country of ref document: ES